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Abstract 
An Invitation: The time has come to examine the ethical dimensions of our pharmaceutical and 
device enterprise more broadly. 
In this inaugural edition of Therapeutic Innovation & Regulatory Science (TIRS), Lipworth et al have 
provided a useful introduction to ethical analysis, a framework to guide ethical discussions, and a 
possible research agenda around the ethical aspects of drug and device development and policy. 
It may seem strange to be proposing that TIRS become the vehicle for the discussion of the ethical 
dimensions of policies on drug, device, and companion diagnostics development. But for too long 
our “industry” has neglected this dimension of our work, to the detriment of all stakeholders, most 
notably the patient/consumer. 
All of us are aware that our standing as an industry has suffered, and most of us would dearly love to 
be recognized as part of a vital enterprise dedicated to improving human health, not only unsullied 
by scandals fuelling the perception of overriding self-interest but also free to explore new ways to 
contribute to society. We are excited that TIRS might become the forum in which new thinking will 
emerge through systematic ethical analyses of pharmaceutical and device policy and practice. 
As Acting Executive Editor and Editorial Board members we hope that you, as a regulator, pre-clinical 
scientist, project manager, patient, clinician, health economist, or other stakeholder, will accept this 
invitation to become involved, and contribute to a stimulating and productive discussion about 
aspects of drug and device development that have been relatively overlooked heretofore. 
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What Is Pharmaceutical Ethics, and What Effects Has It Had? 
Bioethics has long been concerned about issues to do with the development, deployment, and use 
of medicines, but the sub-discipline of pharmaceutical ethics is relatively new. For the most part, 
pharmaceutical ethics has been concerned primarily with the workings of the pharmaceutical 
industry.1,2 Among other things, ethicists have criticized the industry for developing medicines that 
are likely to be commercially successful even if these do not address genuine unmet needs, carrying 
out research without due regard for the well-being of research participants, distorting the design 
and interpretation of research in order to produce more positive findings, withholding negative 
results from publication, overstating the costs involved in research and development in order to 
overprice medicines, misusing intellectual property laws, and engaging in ethically dubious 
marketing practices. Academics, clinicians, journal editors, regulators, and funding bodies have been 
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subject to similar criticisms, largely due to their perceived entanglements with the pharmaceutical 
industry when they have received funding for research, education, regulation, or other activities.3,4  
These concerns have contributed to ever more stringent regulation in the form of, for example, rules 
about the conduct of clinical research (e.g., demands that clinical trials be registered prior to 
carrying them out and that all data be publicly available5), marketing practices (e.g., most countries 
ban direct-to-consumer advertising of prescription pharmaceuticals6 and “off-label” marketing of 
drugs for indications that have not received regulatory approval7), and drug pricing and patenting.8 
There are also more demanding rules governing industry engagement with academic researchers, 
clinicians, regulators, and funding bodies.9  
While few deny that pharmaceutical companies have acted unethically at times, it has also been 
argued that ethicists have focused too much of their attention on the perils of commercialization to 
the exclusion of other concerns. More generally, ethical criticisms and regulatory responses have 
failed to recognize the changing landscape of drug development and regulation, the complexities of 
the commercial world, and the heterogeneity of attitudes, values, and practices within industry. 
This, critics argue, has resulted in a situation in which responses to concerns about industry 
misconduct are not always underpinned by sound evidence of their likely effectiveness in reducing 
harm.10 For example, in recent times, there has been much focus on exposing relationships 
between academics and the pharmaceutical industry,9 but there is little evidence that transparency 
alone is sufficient to change behaviour or prevent harm to the public.11  
 
What Place Should Ethics Have in Pharmaceutical Practice and Policy? 
Those who wish to defend the pharmaceutical industry, or who are critical of the direction that 
pharmaceutical regulation has taken, might therefore be critical of pharmaceutical ethics. People 
with this view might argue that the discipline has little to offer those discovering, testing, regulating, 
marketing, or prescribing medicines and that ethical inquiry should be treated with scepticism.  
However, we would argue against such a dismissive approach for two reasons. First, all of the 
processes that make up pharmaceutical innovation, including drug discovery, testing, regulation, 
marketing, and prescribing—even those that appear to be primarily technical—are actually value 
laden, and all decisions made about these processes have ethical implications. To give an example, a 
public body charged with making decisions about which medicines should be subsidized for patients 
needs to consider not only available scientific evidence and economic calculations but also the 
following12-16:  
 How clinical outcomes should be prioritized: for example, whether to rank survival or quality 
of life, whether thresholds for outcomes should be set, how to measure and evaluate 
incremental benefits, and whether to consider patient-defined benefits;  
 How clinical benefits should be balanced against economic costs: for example, how much we 
are prepared to pay for a particular outcome and what opportunity costs we are prepared to 
incur;  
 How to weigh up and mediate the claims of different populations: for example, how to 
proceed when there is competition for resources between populations that vary in size (e.g., 
those with a rare disease vs those with a common disease), health status (e.g., those with a 
life-threatening disease vs those with apparently minor health problems), socioeconomic 
status, or access to alternative therapies; and  
 How to assess the clinical and economic research methods that have been used to generate 
evidence about therapies: for example, what level(s) of evidence should be deemed 
privileged, how uncertainty should be dealt with, and how the relative merits of different 
technologies should be assessed when they do not have comparative outcomes.  
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These beliefs are, in turn, underpinned by even deeper beliefs, such as those about the goals of 
health care, social justice and equity, and the methods and goals of science.  
These are fundamental questions, and our answers to these questions depend ultimately on what 
we think it means to live a good life and what we believe societies, including their health services, 
should provide. Only ethics can provide the reasoning tools and conceptual frameworks needed to 
formulate and answer such questions.  
A second reason for having an ethical voice in pharmaceutical policy making is that ethics can help us 
to make use of data about stakeholder opinions and preferences. While stakeholder analyses are 
central to pharmaceutical policy making, they inevitably run into the classic philosophical difficulty 
that arises when we try to move from “is” statements (facts) to “ought” statements (ethics).17,18 In 
the context of policy making, the problem is that it is not easy to move from descriptions of 
stakeholder opinions and preferences (which are kinds of empirical “facts” or “is” statements) to 
normative policy decisions (which are “oughts”). Moreover, even if we could somehow overcome 
the fact-value problem, we would still have to contend with situations in which different 
stakeholders have conflicting opinions and preferences. While ethical analysis cannot overcome the 
fact-value problem, it does provide a set of frameworks for drawing together facts and values. These 
approaches, known collectively as “empirical bioethics,” seek to incorporate both empirical data 
(such as data about stakeholder opinions) and normative theory into ethical reflection and decision 
making.19  
Pharmaceutical practice and policy making can thus be enriched by ethics in 2 ways: First, ethics can 
be used to help us to reflect theoretically on the right and the good. Second, it can help us to make 
sense of empirical data, such as data about stakeholder opinions and preferences, and incorporate 
these data into policy decisions.  
 
An Agenda for Pharmaceutical Ethics 
So where should pharmaceutical ethics focus its attention, and how can ethics avoid contributing to 
simplistic or otherwise misguided pharmaceutical policy? First, we suggest that ethical analysis of 
pharmaceutical practice needs to avoid seeing commercialization as a purely negative force. In 
particular, more attention needs to be paid to the fact that medicine has always existed in a 
commercial environment and that the distinction between “academic” and “commercial” activities is 
no longer clear cut. Indeed, many universities and academic medical centres now position 
themselves as “partners” with private industry20 and do not necessarily demand, or even want, 
complete control over the design, conduct, or dissemination of research.21 These subtleties tend to 
be hidden in the somewhat polemical debates about the “evils” of the pharmaceutical industry and 
the importance of protecting the ethically pristine government-funded academic research 
environment.  
Second, we suggest that ethicists need to recognize that the pharmaceutical industry is not the only 
force influencing pharmaceutical innovation. Other influences, which are in need of equal attention, 
include the following, for example22 –28:  
 The impact of national and global financial contexts, notably the recent global financial crisis, 
on the amount of funding available for research and drug development in the public and 
private sectors;  
 The globalization of clinical research and drug manufacturing, particularly to countries in 
Asia, Eastern Europe, and Latin and South America;  
 Challenges to academic research and development, with universities and research 
institutions competing for limited government funding and increasingly forming “public-
private” alliances with industry;  
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 Changing scientific paradigms such as the advent of “pharmacogenomics” in which drugs are 
designed not for whole populations but rather for subpopulations with particular genetic 
profiles;  
 The increasing focus of drug development on chronic, complex, and etiologically 
multifactorial conditions (e.g., psychiatric and neurological disorders and cancers);  
 Changes to national and international approaches to drug regulation and pricing, with an 
increasing focus on premarketing and post marketing risk assessment, health technology 
assessment, comparative effectiveness analysis, and alignment with test approval;  
 Changing consumer expectations, with consumers and patient advocacy groups being 
increasingly interested in ensuring that the research agenda generates the products and 
clinical outcomes that matter to them; and  
 The development of new information technologies and the increasing exploitation of large 
electronic and tissue databases. 
While some of these issues might appear at first glance to be simply about evidence, technology, or 
economics, each of these forces is likely to affect pharmaceutical innovation in ethically relevant 
ways (both positive and negative), and each is likely to be viewed differently by different stakeholder 
groups. In other words, these are all “ethical” issues that require systematic ethical analysis.  
Other topics requiring systematic ethical analysis relate to the development and deployment of 
different kinds of medicines, including the following: how to ensure equitable access to high-cost 
medicines (e.g., expensive biological agents) or to lower cost but still unavailable “essential” 
medicines in resource-poor environments, how to ensure that personalized medicines (and 
associated biomarkers) do not limit the availability of effective therapies to particular populations, 
how to promote the production of medicines for rare diseases (orphan drugs) and medicines for 
neglected populations (e.g., paediatrics, developing world populations), and how to promote the 
availability of generic and bio-similar medicines without stunting innovation. Various phases of the 
pharmaceutical innovation process could also be subjected to more systematic ethical analysis, 
including the ethics of research agenda setting; academic publication; drug, device, and companion 
diagnostics registration; pharmaco-vigilance; health technology assessment; and the production and 
uptake of clinical practice guidelines.  
 
What Role Can Industry and Regulators Play in Developing Pharmaceutical Ethics? 
It follows from the above that members of industry and regulatory bodies, along with consumers 
and clinicians, have much to gain from engaging with ethical ideas. To facilitate this, we invite 
members of DIA to express their interest in joining a Special Interest Area Community (SIAC) focused 
on pharmaceutical ethics. We would also like this journal to be a site for ethical analysis, reflection, 
and debate in the form of research articles, letters, editorials, and opinion pieces. To begin the 
conversation, we will be publishing a series of articles on ethical issues. It is our hope that people will 
engage around ethical questions concerning drug development, regulation, and utilization, 
particularly those that are often misunderstood or unexplored, such as what the costs and benefits 
of regulation really are, whether moves to increase transparency have improved practice or just 
confused it, and whether the policies and practices of industry and government are creating the 
environment in which we are getting the drugs we need.  
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